Ritter Pharmaceuticals, Inc develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance. The company's product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone310-203-1000
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees7
Next Earnings Date11/8/2019 (Estimated)
OptionableNot Optionable
Ritter Pharmaceuticals (NASDAQ:RTTR) Frequently Asked Questions
What is Ritter Pharmaceuticals' stock symbol?
Ritter Pharmaceuticals trades on the NASDAQ under the ticker symbol "RTTR."
When did Ritter Pharmaceuticals' stock split? How did Ritter Pharmaceuticals' stock split work?
Ritter Pharmaceuticals's stock reverse split before market open on Friday, March 23rd 2018. The 1-10 reverse split was announced on Thursday, March 22nd 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, March 22nd 2018. An investor that had 100 shares of Ritter Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.
How were Ritter Pharmaceuticals' earnings last quarter?
Ritter Pharmaceuticals Inc (NASDAQ:RTTR) announced its quarterly earnings results on Wednesday, August, 14th. The biotechnology company reported ($0.31) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.49) by $0.18. View Ritter Pharmaceuticals' Earnings History.
When is Ritter Pharmaceuticals' next earnings date?
What price target have analysts set for RTTR?
1 brokers have issued 12-month target prices for Ritter Pharmaceuticals' stock. Their predictions range from $10,000,000.00 to $0.00. On average, they expect Ritter Pharmaceuticals' share price to reach $0.00 in the next twelve months. This suggests that the stock has a possible downside of 100.0%. View Analyst Price Targets for Ritter Pharmaceuticals.
What is the consensus analysts' recommendation for Ritter Pharmaceuticals?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ritter Pharmaceuticals in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Ritter Pharmaceuticals.
Has Ritter Pharmaceuticals been receiving favorable news coverage?
News stories about RTTR stock have trended negative on Wednesday, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Ritter Pharmaceuticals earned a coverage optimism score of -2.4 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Ritter Pharmaceuticals.
Are investors shorting Ritter Pharmaceuticals?
Ritter Pharmaceuticals saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 492,000 shares, an increase of 36.1% from the August 30th total of 361,500 shares. Based on an average daily volume of 869,400 shares, the short-interest ratio is presently 0.6 days. Currently, 5.8% of the company's shares are short sold. View Ritter Pharmaceuticals' Current Options Chain.
Who are some of Ritter Pharmaceuticals' key competitors?
Some companies that are related to Ritter Pharmaceuticals include Conatus Pharmaceuticals (CNAT), IMMURON LTD/S (IMRN), Eyegate Pharmaceuticals (EYEG), Mabvax Therapeutics (MBVX), Tetraphase Pharmaceuticals (TTPH), GT Biopharma (GTBP), NeuroVive Pharmaceutical (NEVPF), Kaya (KAYS), Capricor Therapeutics (CAPR), MusclePharm (MSLP), X T L Biopharmaceuticals (XTLB), Neurotrope (NTRP), Q BioMed (QBIO), BENITEC BIOPHAR/S (BNTC) and Diffusion Pharmaceuticals (DFFN).
What other stocks do shareholders of Ritter Pharmaceuticals own?
Who are Ritter Pharmaceuticals' key executives?
Ritter Pharmaceuticals' management team includes the folowing people:
- Mr. Ira Eliot Ritter, Co-Founder, Exec. Chairman & Chief Strategic Officer (Age 70)
- Mr. Andrew J. Ritter, Co-Founder, CEO, Pres, Corp. Sec. & Director (Age 36)
- Mr. Michael D. Step, Consultant & Director (Age 59)
- Mr. John W. Beck CPA, CPA, Chief Financial Officer (Age 59)
- Ms. Ellen F. Mochizuki, Consultant (Age 52)
When did Ritter Pharmaceuticals IPO?
(RTTR) raised $20 million in an initial public offering on Wednesday, June 24th 2015. The company issued 4,000,000 shares at $5.00 per share. Aegis Capital Corp and Chardan Capital Markets acted as the underwriters for the IPO and Barrington Research was co-manager.
How do I buy shares of Ritter Pharmaceuticals?
Shares of RTTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Ritter Pharmaceuticals' stock price today?
One share of RTTR stock can currently be purchased for approximately $0.30.
How big of a company is Ritter Pharmaceuticals?
Ritter Pharmaceuticals has a market capitalization of $2.83 million. The biotechnology company earns $-16,870,000.00 in net income (profit) each year or ($3.66) on an earnings per share basis. Ritter Pharmaceuticals employs 7 workers across the globe.View Additional Information About Ritter Pharmaceuticals.
What is Ritter Pharmaceuticals' official website?
How can I contact Ritter Pharmaceuticals?
Ritter Pharmaceuticals' mailing address is 1880 CENTURY PARK EAST SUITE 1000, LOS ANGELES CA, 90067. The biotechnology company can be reached via phone at 310-203-1000 or via email at [email protected]
MarketBeat Community Rating for Ritter Pharmaceuticals (NASDAQ RTTR)
MarketBeat's community ratings are surveys of what our community members think about Ritter Pharmaceuticals and other stocks. Vote "Outperform" if you believe RTTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RTTR will underperform the S&P 500 over the long term. You may vote once every thirty days.
